Resolve Therapeutics Obtains $5,800,000 Series B Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ecbc5abc-bd5d-498f-8ae7-67cb2fce6796&Preview=1
Date
11/1/2012
Company Name
Resolve Therapeutics
Mailing Address
5400 Carillon Point Kirkland, WA 98033
Company Description
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of RSLV-125, its novel targeted biologic therapy.
Website
http://www.resolvebio.com
Transaction Type
Venture Equity
Transaction Amount
$5,800,000
Transaction Round
Series B
Proceeds Purposes
These funds give Resolve the necessary resources to advance our investigational lupus compound RSLV-132 into clinical trials, which we expect to start in mid-2013.
M&A Terms
Venture Investor
New Science Ventures
Venture Investor
WRF Capital
Venture Investor
Easton Capital